Ana Fortuna
Auxiliar Professor FFUC
Group at CNC

Ana Fortuna graduated in Pharmaceutical Sciences at the Faculty of Pharmacy of University of Coimbra, in 2006. In the same year, she got a FCT PhD fellowship with the project entitled “Análise farmacométrica de derivados da carbamazepina: avaliação in vitro, in vivo e in silico das suas propriedades farmacológicas“, which was awarded, in 2012, by Liga Portuguesa contra a Epilepsia.
In 2011, Ana Fortuna achieved the PhD degree in Pharmacology at the Faculty of Pharmacy of University of Coimbra.
Currently she is Auxiliary Professor at Faculty of Pharmacy of the University of Coimbra and a member of the Pharmacometrics Group of the Centre for Neurosciences and Cell Biology, University of Coimbra (Coimbra), Portugal. As a researcher in this group, she has developed new in vitro models and in vivo studies to characterize drug pharmacokinetics and new bioanalytical methods to quantify drugs and metabolites in several biological matrices. Furthermore she is investigating the potential of intranasal administration of anti-epileptic drugs, a work recently (2015) awarded by Liga Portuguesa contra a Epilepsia.
Ana Fortuna is author and co-author of more than 30 international articles and author of two chapter books and co-author of other two chapters.



Area of Research: 

- Development, validation and employment of in vitro techniques to:
•    estimate drugs permeability through intestinal mucosa and blood-brain barrier,
•    estimate drugs plasma protein binding,
•    identify substrates of efflux transporters (e.g. P-glycoprotein, breast cancer receptor protein);
•    characterize the metabolism of new chemical entities.
- In vitro and in vivo pharmacokinetic evaluation of antiepileptic drugs, COMP inhibitors, fluoroquinolones and anti-inflammatory drugs;
- Investigation intranasal administration potential to delivery drugs into the brain or bloodstream in comparison to the most common routes (oral, IV, IP).

 - Development and full validation of bioanalytical methodologies to quantify drugs and metabolites in biological samples by HPLC.

Research Summary:
Selected Publications: 

A. Serralheiro, G. Alves, A. Fortuna, A. Falcão. Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice. International Journal of Pharmaceutics, 2015, 490, 39-46.
Impact Factor: 3.650; Quartil: 1º

A. Fortuna, G. Alves, A. Serralheiro, J. Sousa, A. Falcão. Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. European Journal of Pharmaceutics and Biopharmaceutics. 2014, 88, 8-27. doi: 10.1016/j.ejpb.2014.03.004.
Impact Factor: 3.850; Quartil: 1º

D. Gonçalves, G. Alves, A. Fortuna, P. Soares-da-Silva, A. Falcão. An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma. The Analyst. 2013, 138: 2463-2469.
Impact Factor: 3.969; Quartil: 1º

A. Fortuna, G. Alves, A. Falcão, P. Soares-da-Silva. Evaluation of the Permeability and P-Glycoprotein Efflux of Carbamazepine and several derivatives across Mouse Small Intestine by the Ussing Chamber Technique. Epilepsia. 2012, 53: 529-538
Impact Factor: 3.909; Quartil: 1º

A. Fortuna, J. Sousa, G. Alves, A. Falcão, P. Soares-da-Silva. Development and validation of an HPLC-UV method for the simultaneous quantification of carbamazepine, oxcarbazepine, eslicarbazepine acetate and their main metabolites in human plasma. Analytical and Bioanalytical Chemistry. 2010, 397: 1605-1615.
Impact Factor: 3.659; Quartil: 1º

Financiado por Fundos FEDER através do Programa Operacional Factores de Competitividade – COMPETE 2020 e por Fundos Nacionais através da FCT – Fundação para a Ciência e a Tecnologia no âmbito do projecto Estratégico com referência atribuida pelo COMPETE: POCI-01-0145-FEDER-007440

© 2019 CNC - Center for Neuroscience and Cell Biology
powered by DigitalWind